Device Trial Radar · NCT02871089
Closed Loop From Onset in Type 1 Diabetes
Last checked: Nov 20, 2026Latest source record: May 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
96
Planned (sponsor's estimate)
Start
Jan 2017
Primary completion
Jul 31, 2023
Study completion Jul 31, 2024
Sponsor
- Lead sponsor
- University of CambridgeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cambridge University Hospitals NHS Foundation Trust; Alder Hey Children's NHS Foundation Trust; Nottingham University Hospitals NHS Trust; Oxford University Hospitals NHS Trust; University Hospital Southampton NHS Foundation Trust; Jaeb Center for Health Research; The Leeds Teaching Hospitals NHS Trust; University of Edinburgh
- First posted
- Aug 18, 2016
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- Who can join
- All sexes, from 10 years, up to 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to use a novel treatment approach, the artificial pancreas, after diagnosis of type 1 diabetes (T1D) to improve glucose control with the anticipated improvements of residual C-peptide secretion. This is an open-label, multicentre, single-period, randomised, parallel group design study. It is expected that a total of up to 190 subjects (aiming for 96 randomised subjects) will be recruited within ten working days of diagnosis of type 1 diabetes through paediatric diabetes centres in the UK. Half of the participants aged 10 to 16.9 years will be treated by conventional insulin injections and the other half by the artificial pancreas (closed loop insulin delivery system). Each treatment will last 24 months. All participants completing the 24 month study period will be invited to continue in an optional extension phase with the treatment allocated at randomisation for a further 24 months. Subjects in the intervention group will receive additional training on components of the artificial pancreas, i.e. insulin pump and continuous glucose monitoring (CGM), prior to starting closed loop insulin delivery. Subjects in the control intervention group will continue with standard therapy, i.e. multiple daily injection therapy. The study includes up to 14 visits and 1 telephone/email contact for subjects completing the study. After run-in and randomisation, visits will be conducted every 3 months in both arms. Beta-cell function will be assessed by serial measurement of C-peptide in response to a standardised mixed meal tolerance test (MMTT). MMTTs will be conducted at baseline, 6-,12- and 24 months post diagnosis. The primary outcome is the between group difference in the area under the stimulated C-peptide curve (AUC) of the MMTT at 12 month post diagnosis. Secondary outcomes include between group differences in stimulated C-peptide AUC over 24 months, differences in glycaemic control as assessed by HbA1c, time spent in glucose target range, glucose variability, hypo- and hyperglycaemia as recorded by periodically applied CGM, as well as insulin requirements and change in bodyweight. Additionally, cognitive, emotional and behavioural characteristics of participating subjects and parents will be assessed, and a cost utility analysis on the benefits of closed loop insulin delivery will be performed. Safety evaluation comprises assessment of the frequency of severe hypoglycaemic episodes, diabetic ketoacidosis (DKA) and number, nature and severity of other adverse events.
Conditions
- Diabetes Mellitus
- Type 1 Diabetes
Interventions
Closed-loop system (Florence M or CamAPS FX)Device
The automated closed-loop system (FlorenceM) will consist of: * Sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite/Guardian 3 real time CGM and glucose suspend feature. * An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device. The automated closed-loop system (CamAPS FX) will consist of: * Dana R or RS insulin pump * Dexcom G6 real-time CGM * CamAPS FX App on an unlocked android smartphone. Rapid acting insulin analogue will be used (insulin aspart, insulin lispro, insulin glulisine or similar or ultra-rapid insulin analogue).
Multiple Daily InjectionsOther
Rapid acting insulin analogue and long acting insulin analogue will be subcutaneously administered using CE-marked insulin pen devices in accordance with the manufacturer's instructions for their intended purposes. Participants will be given long acting analogue (insulin glargine, insulin detemir or similar) once or twice daily according to their needs and boluses of rapid acting analogue (insulin aspart, insulin lispro, insulin glulisine or similar or ultra-rapid insulin analogue) when carbohydrates are consumed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the meal stimulated C-peptide curve (AUC) during a mixed meal tolerance test (MMTT)Time frame: 12 months post diagnosis
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom
6 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.